Reports from professional meetings about brain tumors, their diagnosis and treatment.
Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a radomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group.
Presenter: R. StuppPresenter's Affiliation: University Hospital (CHUV), Lausanne, SwitzerlandType of Session: PlenaryBackground Glioblastoma multiforme is the most malignant and most common primary brain tumor, with a dismal median overall survival of less than one year. Radiation treatment has long been the standard of care in treating GBM.
Phase III Trial of BCNU Plus Cisplatin (CDDP) Versus BCNU Alone, and Standard Radiation Therapy (SRT) Versus Accelerated Radiation Therapy (ART) in Glioblastoma (GBM) Patients: NCCTG/SWOG Results
Presenter: J.C. Buckner Affiliation: Mayo Clinic, Rochester, MN Background: The adjuvant treatment for GBM is radiation therapy plus or minus BCNU. With this therapy, the median survival is about 10 months and the 5- year overall survival is about 1%. With such poor outcomes, new therapeutic approaches are needed. This study was designed
A Multicenter, Randomized, Double Blind, Placebo (PB) Controlled Trial of Marimastat (MT) In Patients with Glioblastoma Multiforme (GBM) or Gliosarcoma (GS) Following Completion of Conventional, First-Line Treatment
Presenter: S. Phuphanich Affiliation: The Marimastat Glioblastoma Study Group Background: The standard adjuvant therapy for GBM is radiation therapy with or without BCNU. The outcomes of therapy for GBM or GS are poor. There is clearly a need for novel treatment approaches. This study looks a Marimastat administration as an attempt to
Randomized Prospective Comparison of Stereotactic Radiosurgery (SRS) Followed by Conventional Radiotherapy (RT) with BCNU to RT with BCNU Alone for Selected Patients with Supratentorial Glioblastoma Multiforme (GBM): Report of RTOG 93-05 Protocol.
Presenter: L. SouhamiPresenter's Affiliation: McGill University, Montreal, QC, CanadaType of Session: ScientificBackground GBM continues to prove a most challenging tumor to treat. In spite of aggressive therapy local recurrence remains a significant problem. RTOG 9305 is a prospective randomized trial designed to evaluate upfront SRS followed by
Glioblastoma (GBM) in elderly patients: A randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single-agent chemotherapy (TMZ)
Presentor: A. Malmstrom Affiliation: Unit of Advanced Palliative Home Care, Linköping, Sweden Background Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor, accounting for 40% of primary CNS Malignancies The incidence of GBM increases with age and approximately 50% of patients diagnosed with GBM are > 65